Plain-English translation of NCT04437160 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether patients with triple negative breast cancer who still have cancer left after initial chemotherapy and surgery benefit from receiving additional rounds of chemotherapy using drugs called epirubicin (or pirarubicin) combined with . Half of the participants will receive this extra medication, while the other half will be observed without additional treatment to see which approach leads to better outcomes.
Even after receiving chemotherapy before surgery and having the tumor removed, some patients with triple negative breast cancer still have cancer cells remaining. Doctors want to know whether giving more chemotherapy at this point can prevent the cancer from coming back and help patients live longer.
You likely qualify if…
You likely don't qualify if…
After surgery, you will be randomly assigned to either receive 4 cycles of additional chemotherapy given every 3 weeks, or to be observed without extra treatment. If you receive the medication, you will come in for infusions and have regular blood and tissue samples collected. Either way, you will be followed with check-in appointments every 3 to 6 months for an extended period so doctors can track whether your cancer comes back and how you are doing overall.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
China